Hodnota metriky EBITDA spoločnosti China Health Group Inc. je ¥33.415M
EBITDA je zisk pred odpočítaním úrokov, daní, odpisov, a amortizácie reprezentujúci operačnú výkonnosť spoločnosti.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
China Health Group Inc., an investment holding company, provides clinical research services to pharmaceutical and biotechnology companies in the People's Republic of China. The company offers contracted clinical research services; contracted pharmaceutical development services; post launch market research, medical, and medical market services; medical science liaisons; and other medical services. It also provides hospital management, medical tourism, and specialized hospital services, as well as Venturepharma cloud; and sells drug technologies. The company was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in January 2015. China Health Group Inc. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.